Vir Biotechnology to Participate in HC Wainwright’s 4th Annual Hepatitis B Virus (HBV) Conference

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Philosophy, Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research Dr. Will participate in a virtual fireside Q&A at HC Wainwright’s 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25 at 7:00 am PT/10:00 am ET.

You can view the live webcast of the Fireside Chat on the Investor section of Vir’s website at www.vir.bio under “Events and Presentations” and it will be archived there for 30 days.

About Vir BiotechnologyVir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious diseases. Vir has assembled two technology platforms designed to stimulate and enhance the immune system by leveraging key observations of natural immune processes. Its current clinical development pipeline includes product candidates targeting hepatitis B and D viruses, influenza A and B, human immunodeficiency virus and COVID-19. Vir has multiple preclinical drug candidates in development, including candidates targeting RSV/MPV and HPV. Vir frequently posts information on its website that may be important to investors.

Contacts:

Media
Carly Scaduto
Senior Director, Media Relations
(email protected)
+1 314-368-5189

Investors
Sasha Damouni Ellis
Executive Vice President, Chief Corporate Affairs Officer
(email protected)
 

Source: Vir Biotechnology, Inc.